|0.0627||-0.0023||-3.54%||Vol 10.44K||1Y Perf -95.61%|
|Nov 29th, 2023 13:16 DELAYED|
|- -||- -%|
|Target Price||-||Analyst Rating||— — 0.00|
|Potential %||-||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||1.53||Earnings Rating||—|
|Market Cap||1.93M||Earnings Date||9th Nov 2023|
Today's Price Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||162.78K|
|Avg. Monthly Volume||172.38K|
|Avg. Quarterly Volume||159.07K|
Comera Life Sciences Holdings Inc. (NASDAQ: CMRA) stock closed at 0.065 per share at the end of the most recent trading day (a -6.81% change compared to the prior day closing price) with a volume of 191.40K shares and market capitalization of 1.93M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 0 people. Comera Life Sciences Holdings Inc. CEO is Jeffrey S. Hackman.
The one-year performance of Comera Life Sciences Holdings Inc. stock is -95.61%, while year-to-date (YTD) performance is -94.72%. CMRA stock has a five-year performance of %. Its 52-week range is between 0.03 and 2.17, which gives CMRA stock a 52-week price range ratio of 1.53%
Comera Life Sciences Holdings Inc. currently has a PE ratio of -0.90, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of 79.11, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -351.49%, a ROC of -% and a ROE of 506.23%. The company’s profit margin is -%, its EBITDA margin is -3 096.80%, and its revenue ttm is $476.98 Thousand , which makes it $0.02 revenue per share.
Of the last four earnings reports from Comera Life Sciences Holdings Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Comera Life Sciences Holdings Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Comera Life Sciences Holdings Inc. is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Comera Life Sciences Holdings Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Comera Life Sciences Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Comera Life Sciences Holdings Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 41.83, ATR14 : 0.04, CCI20 : -92.20, Chaikin Money Flow : -0.11, MACD : -0.07, Money Flow Index : 58.96, ROC : -81.43, RSI : 28.30, STOCH (14,3) : 10.15, STOCH RSI : 0.94, UO : 26.94, Williams %R : -89.85), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Comera Life Sciences Holdings Inc. in the last 12-months were: Barbara K. Finck (Buy at a value of $8 310), Edward Sullivan (Buy at a value of $13 504), Jim Sherblom (Buy at a value of $99 730), Kirsten Flowers (Buy at a value of $16 621), Roopom Banerjee (Buy at a value of $24 932), Soane David (Buy at a value of $139 986), Stuart A. Randle (Buy at a value of $41 553)
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.